The strategy of targeting EGFR and MET can potentially overcome resistance of EGFR-TKI and improve patient outcomes. YH013 is a fully-human EGFR x MET bispecific ADC developed using proprietary RenLiteTM platform with common light chain and knobs-into-holes technology. YH013 showed greater internalization activity, robust anti-tumor efficacy in NSCLC and PDAC PDX models co-expressing EGFR and MET, and outperformed benchmark antibodies at a lower dose (3 mg/kg). These results suggest that by optimizing specificity and improving safety profiles of EGFR-targeting ADCs, YH013 can be an effective subsequent treatment option for MET-driven EGFR-TKI resistant NSCLCs.